METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease. 23.-. (canceled)4. The compound of claim 1 , wherein v is 1.5. The compound of claim 1 , wherein M is a covalent bond or a C-Calkyl.612.-. (canceled)13. The compound of claim 1 , wherein B is —CH(M-W)—CH—CH— claim 1 , —CH—CH(M-W)—CH— claim 1 , or —(CH)—CH—CH(M-W)—.1416.-. (canceled)1861.-. (canceled)62. A compound of Table 3A or Table 3B claim 1 , or a pharmaceutically acceptable salt claim 1 , ester claim 1 , or prodrug thereof.63. (canceled)64. A method of treating or preventing an amyloid-related disease in a subject comprising administering to a subject in need thereof a compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , in an amount effective to treat or prevent an amyloid related disease.65. The method according to claim 64 , wherein said amyloid-related disease is Alzheimer's disease claim 64 , cerebral amyloid angiopathy claim 64 , inclusion body myositis claim 64 , macular degeneration claim 64 , MCI claim 64 , or Down's syndrome.67. (canceled)68. The method according to claim 64 , wherein said amyloid-related disease is diabetes claim 64 , AA amyloidosis claim 64 , AL amyloidosis claim 64 , ATTR-related amyloidosis claim 64 , or hemodialysis related amyloidosis (βM).6971.-. (canceled)72. A method for treating or preventing an amyloid-related disease in a subject in need thereof claim 17 , comprising administering to said subject a therapeutic compound of claim 17 , or a pharmaceutically acceptable salt thereof claim 17 , in an amount effective to treat or prevent an amyloid related disease.73. A method for treating or preventing an amyloid-related disease in a subject in need thereof claim 62 , comprising administering to said subject a therapeutic compound of claim 62 , or pharmaceutically acceptable salts thereof claim 62 , in an amount effective to treat or prevent an amyloid related disease.74120.-. ( ...

METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease. 1232-. (canceled)234. The compound of claim 233 , wherein Ris hydrogen.235. The compound of claim 233 , wherein Ris straight chain alkyl.236. The compound of claim 233 , wherein Ris t-butyl.237. The compound of claim 233 , wherein Ris carbocyclic.238. The compound of claim 233 , wherein Ris C-Cbicycloalkyl.239. The compound of claim 233 , wherein said bicyclic fused ring group is indolyl.240. The compound of claim 233 , wherein Lis CHCHor absent.251. A method of treating or preventing an amyloid-related disease in a subject comprising administering to a subject in need thereof a compound of in an amount effective to treat or prevent an amyloid related disease.252. The method according to claim 251 , wherein said amyloid-related disease is Alzheimer's disease claim 251 , cerebral amyloid angiopathy claim 251 , inclusion body myositis claim 251 , macular degeneration claim 251 , MCI claim 251 , or Down's syndrome.253. The method according to claim 251 , wherein amyloid fibril formation or deposition claim 251 , neurodegeneration claim 251 , microglial inflammatory response claim 251 , or cellular toxicity is reduced or inhibited upon administration of said compound.254. The method according to claim 251 , wherein said amyloid-related disease is diabetes claim 251 , AA amyloidosis claim 251 , AL amyloidosis claim 251 , or hemodialysis related amyloidosis (βM).255. The method of claim 251 , wherein said subject has Alzheimer's disease claim 251 , Mild Cognitive Impairment claim 251 , or cerebral amyloid angiopathy claim 251 , and stabilization of cognitive function claim 251 , prevention of a further decrease in cognitive function claim 251 , or prevention claim 251 , slowing claim 251 , or stopping of disease progression occurs in said patient upon administration.256. A method for inhibiting amyloid deposition in a subject comprising administering ...

METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease. 23-. (canceled)4. The compound of claim 1 , wherein v is 1.5. The compound of claim 1 , wherein M is a covalent bond or a C-Calkyl.612-. (canceled)13. The compound of claim 1 , wherein B is —CH(M-W)—CH—CH—. —CH—CH(M-W)—CH— claim 1 , or —(CH)—CH—CH(M-W)—.1416-. (canceled)1861-. (canceled)62. A compound of Table 3A or Table 3B claim 1 , or a pharmaceutically acceptable salt claim 1 , ester claim 1 , or prodrug thereof.63. (canceled)64. A method of treating or preventing an amyloid-related disease in a subject comprising administering to a subject in need thereof a compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , in an amount effective to treat or prevent an amyloid related disease.65. The method according to claim 64 , wherein said amyloid-related disease is Alzheimer's disease claim 64 , cerebral amyloid angiopathy claim 64 , inclusion body myositis claim 64 , macular degeneration claim 64 , MCI claim 64 , or Down's syndrome.66. (canceled)67. The method according to claim 64 , wherein said amyloid-related disease is diabetes claim 64 , AA amyloidosis claim 64 , AL amyloidosis claim 64 , ATTR-related amyloidosis claim 64 , or hemodialysis related amyloidosis (βM).6870-. (canceled)71. A method for treating or preventing an amyloid-related disease in a subject in need thereof claim 17 , comprising administering to said subject a therapeutic compound of claim 17 , or a pharmaceutically acceptable salt thereof claim 17 , in an amount effective to treat or prevent an amyloid related disease.72. A method for treating or preventing an amyloid-related disease in a subject in need thereof claim 62 , comprising administering to said subject a therapeutic compound of claim 62 , or pharmaceutically acceptable salts thereof claim 62 , in an amount effective to treat or prevent an amyloid related disease.73119-. (canceled)120. The ...

Stereoselective antifibrillogenic peptides and peptidomimetics thereof

The present invention relates to antifibrillogenic agents for inhibiting amyloidosis and/or for cytoprotection for the treatment amyloidosis disorders. These agents include peptides, isomers thereof and peptidomimetic compounds thereof. These agents comprise peptide having a sequence identified from the glycosaminoglycan (GAG) binding region and the prot—prot interaction region of the amylo protein. The peptide has at least one [D] amino acid isomer substitution. The invention also relates to the peptide bound to a label for vivo imaging of amyloid deposits.

Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases

The present invention relates to a stereochemically based “non-self” antigen vaccine for the prevention and/or treatment of Alzheimer's and other amyloid related diseases. The present invention provides a vaccine for the prevention and treatment of Alzheimer's and other amyloid related diseases, which overcomes the drawbacks associated with using naturally occurring peptides, proteins or immunogens.

Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases

The present invention relates to a stereochemically based "non-self" antigen vaccine for the prevention and/or treatment of Alzheimer's and other amyloid related diseases. The present invention provides a vaccine for the preventio n and treatment of Alzheimer's and other amyloid related diseases, which overcomes the drawbacks associated with using naturally occurring peptides, proteins or immunogens.

Therapeutic formulations for the treatment of beta-amyloid related diseases

Therapeutic formulations for the treatment of beta-amyloid related diseases

This invention relates to methods and pharmaceutical compositions for treating amyloid-β related diseases, including Alzheimer's disease. The invention, for example, includes a method of concomitant therapeutic treatment of a subject, comprising administering an effective amount of a first agent and a second agent, wherein said first agent treats an amyloid-β disease, neurodegeneration, or cellular toxicity; and said second agent is a therapeutic drug or nutritive supplement.

Methods and compositions for treating amyloid-related diseases

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

Methods and compositions for treating amyloid-related diseases

Abstract Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

Methods and compositions for treating amyloid-related diseases

Therapeutic formulations for the treatment of beta-amyloid related diseases

Disclosed is a combination of 3-aminopropanesulfonic acid or sodium 3-aminopropanesulfonate or pharmaceutically acceptable salts thereof with a second agent selected from cholinesterase inhibitors and NMDA receptor antagonists. The combination is useful for the treatment of an amyloid-beta related disease or condition.

Compounds for the treatment of cns and amyloid associated diseases

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing CNS and amyloid associated disease. Also described are methods, compounds, pharmaceutical compositions and kits for detecting, diagnosing, monitoring and treating or preventing CNS and amyloid associated disease Pn particular, modified blood bram barrier (BBB) vectors such as phenylalanine derivatives are described as to provide parameters to select CNS drug candidates designated to penetrate the bram using a specific active transporter.

Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases

The present invention relates to a stereochemically based 'non-self' antigen vaccine for the prevention and/or treatment of Alzheimer's and other amyloid related diseases. The present invention provides a vaccine for the prevention and treatment of Alzheimer's and other amyloid related diseases, which overcomes the drawbacks associated with using naturally occurring peptides, proteins or immunogens.

Methods and compositions for treating amyloid-related diseases

Abstract Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

Therapeutic formulations for the treatment of beta-amyloid related diseases

Methods and compositions for treating amyloid-related diseases

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

Therapeutic formulations for the treatment of beta-amyloid related diseases

Therapeutic formulations for the treatment of beta-amyloid related diseases

The method is used for preventing or treating an amyloid-.beta. related disease in a subject. The method comprises administering to a subject in nee d thereof an effective amount of a first agent that prevents or treats amyloid - .beta. related disease, and a second agent that is (i) a peptide or peptidomimetic that modulates amyloid-.beta. fibril formulation or induces a prophylactic or therapeutic immune response against amyloid-.beta. fibril formulation, or (ii) an immune system modulator that prevents or inhibits amyloid-.beta. fibril formulation.

Method and compositions for treating amyloid-related diseases

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

Methods and compositions for treating amyloid-related diseases

Compounds of formulae (VIII), (IX), (X), (XI), (XII) (XIII), (XIV) and (XV), in which the variables are as defined in the claims are described, as well as methods, pharmaceutical compositions and kits for treating or preventing amyloid-related disease.

Methods and compositions for treating amyloid-related diseases

Abstract Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

Methods and compositions for treating amyloid-related diseases

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-+ related disease.

Methods and compositions for treating amyloid-related diseases

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

Therapeutic formulations for the treatment of beta-amyloid related diseases

Methods and compositions for treating amyloid-related diseases

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-+ related disease.

Amyloid targeting imaging agents and uses thereof

Amyloid-targeting imaging agents such as radiolabeled amyloid targeting molecules and amyloid targeting molecule-chelator conjugates for imaging, e.g., amyloid plaques in vivo, and/or for the treatment of amyloidosis disorders. The invention provides amyloid-targeting imaging agents that are useful for imaging sites of amyloid disease. Imaging agents of the invention are capable of binding specifically to amyloid plaques, as an aid in diagnosis and/or early treatment of amyloidosis disorders.

Methods and compositions to treat glycosaminoglycan-associated molecular interactions

Therapeutic compounds and methods for inhibiting a glycosaminoglycan (GAG)-associated molecular interaction in a subject, whatever its clinical setting, are described.

Use of amyloid inhibitors for modulating neuronal cell death

Method for modulating macrophage activation

Methods and compositions for the treatment of amyloid-related diseases

Metoder, forbindelser, farmasøytiske preparater og sett er beskrevet for behandling eller forhindring av amyloid-relatert sykdom.

Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases comprising all-d peptides

Method for modulating macrophage activation

Anionic compounds, including sulfonates, are capable of blocking A.beta.-induced macrophage activation (or macrophage activation induced by other amyloidogenic proteins or peptides). Such compounds can inhibit the inflammatory process, e.g., in the brain of a subject suffering from a disease characterized by A.beta. deposition, such as Alzheimer's disease.

Methods and compositions for treating amyloid-related diseases

Disclosed are compounds of formula V wherein A is NH or oxygen and aa is a natural or unnatural amino acid residue and the remaining substituents are as defined in the specification, and their use in treating amyloid-related diseases such as Alzheimer's disease, cognitive impairment and Down's syndrome. (62) (62) Divided Out of 544684

Methods and compositions for treating amyloid-related diseases

Compounds of formulae (VIII), (IX), (X), (XI), (XII) (XIII), (XIV) and (XV), in which the variables are as defined in the claims are described, as well as methods, pharmaceutical compositions and kits for treating or preventing amyloid-related disease.

Stereoselective antifibrillogenic peptides and peptidomimetics thereof

The present invention relates to antifibrillogenic agents for inhibiting amyloidosis and/or for cytoprotection for the treatment of amyloidosis disorders. These agents include peptides, isomers thereof and peptidomimetic compounds thereof. These agents comprise a peptide having a sequence identified from the glycosaminoglycan (GAG) binding region and the prot-prot interaction region of the amyloid protein. The peptide has at least one [D] amino acid isomer substitution. The invention also relates to the peptide bound to a label for <i>in vivo</i> imaging of amyloid deposits.

Impfstoff zur verhütung und behanldung von alzheimer-demenz und von amyloid-bezogenen krankheiten

立體有擇抗原纖維基因肽及其肽擬態物

Method for modulating macrophage activation

Anionic compounds, including sulfonates, are capable of blocking Aβ-induced macrophage activation (or macrophage activation induced by other amyloidogenic proteins or peptides). Such compounds can inhibit the inflammatory process, e.g., in the brain of a subject suffering from a disease characterized by Aβ deposition, such as Alzheimer's disease.

Method for modulating macrophage activation

Μεθοδος για ρυθμιση ενεργοποιησης μακροφαγου

Ανιονικές ενώσεις, που συμπεριλαμβάνουν σουλφονικά είναι ικανές αναστολής διεγειρόμενης από Αβ ενεργοποίησης μακροφάγου (ή ενεργοποίηση μακροφάγου που διεγείρεται από άλλες αμυλοειδογονικές πρωτεΐνες ή πεπτίδια). Τέτοιες ενώσεις μπορεί να αναστέλλουν τη φλεγμονώδη διεργασία, π.χ., εγκέφαλο ενός υποκειμένου που υποφέρει από μια ασθένεια που χαρακτηρίζεται από απόθεση Αβ, όπως ασθένεια Alzheimer.

Methods and Compositions for Treating Amyloid-Related Diseases

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-+related disease.

Methods and compositions for treating amyloid-related diseases

Methods and compositions for treating amyloid-related diseases